US$ 24.00
cagrilintide clinical trials Once-weekly for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial The next frontier in metabolic
Description
This formulation is currently under review by the FDA, with a decision expected by the end of 2025

Lower cardiac output
This is the most conservative protocol and serves as the starting point for patients who are new to peptide therapy or who have multiple mild concerns rather than one acute target
J Virol (2014) 88(14):782842
